Immunophotonics to Present at the 2024 ThinkEquity Conference Immunophotonics to Present at the 2024 ThinkEquity Conference

Immunophotonics, Inc. Announces First Patient Dosed in a Randomized, Controlled Breast Cancer Clinical Trial for inCVAX – A Novel Investigational Immuno-Oncology Therapy ST. LOUIS, Aug. 23, 2016 (GLOBE NEWSWIRE) -- Immunophotonics today announces that it has dosed its first patient in a randomized & controlled clinical trial to further evaluate the efficacy of...